Pyrazoline Compounds as Non-steroidal Mineralocorticoid Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antihypertensive drugs, particularly mineralocorticoid receptor antagonists, have varying efficacy and safety, and there is a need for non-steroidal compounds to treat hypertension and related cardiovascular and renal issues, as steroidal compounds have limitations in selectivity and complexity of synthesis.
Innovation Solution
Development of a class of pyrazoline compounds with specific structures, including Formula II, which act as non-steroidal mineralocorticoid receptor antagonists, potentially offering improved selectivity and simpler, cost-effective synthesis options.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroidal mineralocorticoid receptor antagonists are used, then therapeutic efficacy is achieved, but selectivity with respect to sex hormone receptors is reduced and synthesis complexity increases
Solution Approach 1:
The patent changes the fundamental structural parameter from steroidal to non-steroidal (pyrazoline) framework, maintaining therapeutic efficacy while simplifying synthesis and improving selectivity. This structural parameter change allows the compound to achieve the desired pharmacological effect without the complexity and selectivity issues of steroidal analogs.
2Reliability
If steroidal mineralocorticoid receptor antagonists are used, then therapeutic efficacy is achieved, but selectivity with respect to sex hormone receptors is reduced
Solution Approach 1:
The patent changes the molecular structure parameter from steroidal to non-steroidal pyrazoline framework, which inherently provides better selectivity for the mineralocorticoid receptor while reducing interactions with sex hormone receptors. This structural modification eliminates the harmful lack of selectivity while preserving therapeutic efficacy.
3Ease of manufacture
If non-steroidal mineralocorticoid receptor antagonists are developed, then selectivity and synthesis simplicity are improved, but novel compound classes must be identified and optimized
Solution Approach 1:
The patent segments the molecular structure into distinct functional components (pyrazoline core, aromatic substituents, carboxylic acid group) that can be independently optimized. This segmentation allows systematic exploration of structure-activity relationships while maintaining the overall non-steroidal framework, facilitating both synthesis simplicity and targeted optimization.
Solution Approach 2:
The patent creates a universal pyrazoline scaffold that can accommodate various aromatic substituents and side chains, allowing a single core structure to serve multiple therapeutic purposes. This multi-functionality enables the compound class to address different optimization goals while maintaining synthesis simplicity through the common core structure.
Data Source
AI summary
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.